Working... Menu

Rilonacept for Treatment of Autoimmune Neurosensory Hearing Loss

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02828033
Recruitment Status : Recruiting
First Posted : July 11, 2016
Last Update Posted : September 13, 2017
Regeneron Pharmaceuticals
Information provided by (Responsible Party):
Stanley Cohen, Metroplex Clinical Research

Brief Summary:
This study is an open label proof of concept study of rilonacept for patients with ANSHL

Condition or disease Intervention/treatment Phase
Autoimmune Neurosensory Hearing Loss (ANSHL) Drug: Rilonacept Early Phase 1

Detailed Description:
Ten (10) patients in total will be enrolled in this study at Metroplex Clinical Research Center in Dallas, TX. Patients may be identified and referred by local area audiologist. The ANSHL study population will be defined by inclusion and exclusion criteria designed to limit enrollment to individuals with idiopathic, progressive, bilateral sensorineural hearing loss, to ensure appropriate candidates for treatment with study medications, and to identify those with a high likelihood of complying with the study protocol.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Trial of Rilonacept for Treatment of Autoimmune Neurosensory Hearing Loss
Actual Study Start Date : February 1, 2017
Estimated Primary Completion Date : March 2018
Estimated Study Completion Date : March 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Rilonacept

Arm Intervention/treatment
Experimental: Rilonacept
A loading dose of 320 mg the first dose then be a once-weekly injection of 160 mg for 24 weeks
Drug: Rilonacept
All patients will receive rilonacept with an initial loading dose of 320 mg delivered as two, 2-mL, subcutaneous injections of 160 mg each given on the same day at two different sites. The initial dose will be administered at the study site by study personnel. Dosing will then be a once-weekly injection of 160 mg administered as a single, 2-mL, subcutaneous injection by the patient at home. Patients will be dosed for 24 weeks.
Other Names:
  • IL-1 Trap
  • Arcalyst

Primary Outcome Measures :
  1. Improvement in hearing in comparison to baseline values [ Time Frame: 24 weeks ]
    1. An improvement in pure tone average (500 to 3000 Hz) by 10 dB in at least one ear or
    2. An improvement of word identification score of at least 12 percent; both relative to baseline values

Secondary Outcome Measures :
  1. Pt reported evaluation of auditory acuity [ Time Frame: 24 weeks ]
    Pt reported evaluation of auditory acuity as measured on a 0-100 Visual Analog Scale (VAS). Patients with a 25% improvement in VAS will be considered responders.

  2. Vertigo evaluation [ Time Frame: 24 weeks ]
    Vertigo will be evaluated using the validated OTA Dizziness Handicap Inventory (DHI). A change in category is considered clinically significant.

  3. Tinnitus evaluation [ Time Frame: 24 weeks ]
    Tinnitus will be evaluated using the validated OTA Tinnitus Handicap Inventory (THI). A change of 6 points on this scale is considered clinically meaningful.

  4. Quality of Life assessment [ Time Frame: 24 weeks ]
    Validated auditory quality of life questionnaire- Response is defined as a 5% or greater improvement

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. The presence of progressive sensironeural hearing loss greater than or equal to 30 dB in both ears at one or more frequencies (250, 500, 1000, 2000, 3000, 4000, 6000 or 8000 Hz) and idiopathic-based on clinical evaluation, blood tests, and radiographic imaging.
  2. Documented improvement in hearing by audiogram after 30 days of treatment with high dose prednisone 40-60 mg/d. Improvement is defined by 10 dB improvement in pure tone average (500-3000 dB) or an improvement in word identification score of at least 12% in either ear (both relative to baseline). Prednisone could be started at screening but patients may have received prednisone prior to screening and the pre prednisone audiogram will be used as the screening audiogram for this study. It is expected the majority of these patients will screen for the study in this fashion as they are referred from otoloaryngology after initial treatment.
  3. 18-75 years of age
  4. Able and willing to give written informed consent and comply with the requirements of the study protocol
  5. Negative serum pregnancy test (for women of child bearing potential). Males and Females of child bearing potential must agree to consistently use 2 forms of highly effective birth control (at least 1 of which must be a barrier method) starting at screening and throughout the study period and for 3 months after the final study drug administration.

Exclusion Criteria:

  1. Pregnant or nursing, or planning to become pregnant or father a child within 3 months after receiving the last dose of study drug
  2. Have a known or suspected current active infection or a history of chronic or recurrent infectious disease including, but not limited to, chronic renal infection, chronic chest infections, chronic sinusitis, recurrent urinary tract infections, an open, draining, infected skin wound.
  3. Within 2 months of first study drug administration, have had a serious infection, have been hospitalized for an infection, have been treated with PO antibiotics for longer than 2 weeks, or have been treated with intravenous (IV) antibiotics for an infection
  4. Uncontrolled diabetes at the baseline visit (defined as HbA1c ≥9.0%)
  5. Patients requiring dialysis
  6. Patients who have had an organ transplant
  7. Treatment with any systemic {non-glucocorticoid} immunosuppressants (e.g. methotrexate, azathioprine, cyclosporine, mercaptopurine, mycophenolate mofetil, tacrolimus, sirolimus within 4 weeks of baseline rilonacept administration. No leflunomide treatment within 8 weeks prior to baseline administration. No etanercept, adalimumab, infliximab, tocilizumab, abatacept, or natalizumab, within 2 months prior to baseline visit; No rituxan for 12 months prior to baseline and evidence of normal B cell count required. Patients previously treated with anakinra for ANSHL cannot be enrolled.
  8. Prohibited Medications:

    1. Strong CYP3A4 inhibitors, protease inhibitors or P-gp inhibitors.
    2. Long-acting or extended release forms of opiates.
    3. Live or live-attenuated vaccines are excluded during the course of the study
    4. IA and IM glucocorticoid injections. Long-acting steroid preparations are not allowed during study (this includes suspensions and all forms of dexamethasone).
  9. History of a demyelinating disease or symptoms suggestive of multiple sclerosis
  10. Treatment with a live or live-attenuated virus vaccine during the 3 months prior to baseline
  11. Estimated glomerular filtration rate (eGFR) of <20 mL/min/1.73m2 or patients planning to start dialysis within a year from the screening visit
  12. Baseline laboratory test results meeting any of the following criteria:

    1. Hemoglobin (Hgb)<8.5 g/dL (85 g/L)
    2. Neutrophil count<1.5 x 103/μL
    3. Platelet count<100 x 103/μL
    4. Total bilirubin exceeding 1.5 times the upper limit of normal (ULN) unless consistent with Gilbert's syndrome
    5. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) exceeding 2 times the ULN
  13. Positive history of human immunodeficiency virus (HIV) by clinical or serological testing.
  14. Presence of hepatitis B surface antigen (HBsAg) and/or hepatitis C antibody (HCV) by serologic testing
  15. History of active TB prior to screening or chest x-ray showing evidence of malignancy or any abnormalities suggestive of prior tuberculosis (TB) infection, including, but not limited to, apical scarring, apical fibrosis, or multiple calcified granulomata.
  16. A positive intradermal skin tuberculin test (purified protein derivative [PPD] 5 tuberculin unit [TU]) of ≥5 mm induration read at 48 to 72 hours or positive QuantiFERON-gold testing. Signs or symptoms suggestive of active TB (e.g. new cough lasting >14 days or a change in chronic cough, persistent fever, unintentional weight loss, night sweats) upon review of medical history and/or physical examination. If the patient is thought to have a false-positive PPD because of prior BCG vaccination and it is known that the patient has been negative on testing obtained outside the protocol for M. tuberculosis infection using a cell-based interferon gamma assay the patient is eligible for enrollment.
  17. Recent close contact with a person with active TB
  18. History of latent untreated TB. Patients who have been adequately treated for latent TB are eligible for enrollment.
  19. Any other medical condition that in the opinion of the investigator could adversely affect the patient's participation or interfere with evaluations. This includes significant concomitant illness such as, but not limited to, cardiac, renal, neurological, endocrinological, metabolic, pulmonary, gastrointestinal, or psychiatric disease.
  20. History or presence of malignancy within 5 years of the screening visit (other than a successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix)
  21. History of a myeloproliferative disorder
  22. History of alcohol abuse within last 5 years or current intake of 21 or more alcohol-containing drinks per week
  23. History of drug abuse within the 5 years prior to screening
  24. Patients with previous exposure to rilonacept
  25. Use of any investigational drug within 30 days or within 5 half-lives (whichever is longer) prior to the screening visit
  26. Sexually active men or women of childbearing potential who are unwilling to practice adequate contraception during the study (adequate contraceptive measures are defined as the use of two highly effective forms of birth control, include stable use of oral contraceptives or other prescription pharmaceutical contraceptives; intrauterine device; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly)
  27. Known moderate-to-severe liver disease (Child-Pugh class B or C)
  28. Known hypersensitivity to CHO cell derived therapeutics or proteins or any components of rilonacept

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02828033

Layout table for location contacts
Contact: Stanley B Cohen, MD 214-879-6737
Contact: Cindy Cabrera 214-879-6737

Layout table for location information
United States, Texas
Metroplex Clinical Research Center Recruiting
Dallas, Texas, United States, 75231
Contact: Cindy Cabrera    214-879-6737   
Contact: Tonja Hill    214-879-6737   
Sponsors and Collaborators
Stanley Cohen
Regeneron Pharmaceuticals
Layout table for investigator information
Principal Investigator: Stanley B Cohen, MD Metroplex Clinical Research Center

Kitashara M, Yazawa.Y, Uchida K. Immunoglobulin treatment for advance cases of bilateral Meniere's disease. In: Nadol JB ed. Meniere's disease: pathogenesis, pathophysiology, diagnosis and treatment. Berkeley, Ca: Kugler Publications; 1989; 411-419.

Layout table for additonal information
Responsible Party: Stanley Cohen, MD, Metroplex Clinical Research Identifier: NCT02828033     History of Changes
Other Study ID Numbers: Rilonacept IIS 1604
First Posted: July 11, 2016    Key Record Dates
Last Update Posted: September 13, 2017
Last Verified: September 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Outcomes data

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Hearing Loss
Hearing Disorders
Ear Diseases
Otorhinolaryngologic Diseases
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Anti-Inflammatory Agents